Vi­iV Health­care looks to make long-act­ing HIV pre­ven­tion shot ac­ces­si­ble in low- and mid­dle-in­come coun­tries

The Joint Unit­ed Na­tions Pro­gramme on HIV and AIDS set a lofty goal back in 2019 to end the HIV epi­dem­ic by 2030. But ac­cord­ing to the World Health Or­ga­ni­za­tion, in­fec­tion rates are not falling rapid­ly enough to meet that tar­get.

GSK’s Vi­iV Health­care thinks it can help change that.

On Fri­day, Vi­iV an­nounced that it’s in talks with the UN-backed Med­i­cines Patent Pool (MPP) for patent rights to its cabote­gravir long-act­ing HIV in­jectable for pre-ex­po­sure pro­phy­lax­is (PrEP) in low- and mid­dle-in­come coun­tries.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN